- Home
- NMTC vs ESLA Comparison
NMTC vs ESLA Comparison
Compare NMTC & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NMTC | ESLA |
|---|---|---|
| Founded | 2009 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 44.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NMTC | ESLA |
|---|---|---|
| Price | $0.78 | $1.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.23 | ★ $8.00 |
| AVG Volume (30 Days) | 266.1K | ★ 345.7K |
| Earning Date | 02-12-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,097,692.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $32.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 250.35 | N/A |
| 52 Week Low | $0.40 | $0.73 |
| 52 Week High | $1.25 | $3.15 |
Technical Indicators
Market Signals| Indicator | NMTC | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 38.63 | 51.30 |
| Support Level | $0.81 | $1.02 |
| Resistance Level | $0.87 | $1.21 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 6.43 | 54.98 |
Price Performance
Historical ComparisonAbout NMTC NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.